ENDRA Life Sciences Inc. (NDRA)
NASDAQ: NDRA · Real-Time Price · USD
5.28
-0.02 (-0.47%)
Oct 28, 2025, 4:00 PM EDT - Market closed
Company Description
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound.
The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
ENDRA Life Sciences Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | May 9, 2017 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Alexander Tokman |
Contact Details
Address: 3600 Green Court, Suite 350 Ann Arbor, Michigan 48105-1570 United States | |
| Phone | 734 335 0468 |
| Website | endrainc.com |
Stock Details
| Ticker Symbol | NDRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001681682 |
| CUSIP Number | 29273B104 |
| ISIN Number | US29273B3024 |
| Employer ID | 26-0579295 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Alexander Y. Tokman | Chief Executive Officer and Chairman |
| Richard Jacroux | Chief Financial Officer and Secretary |
| Michael Thornton Ph.D. | Chief Technology Officer |
| Dr. Jonathan Behr Ph.D. | Co-Founder |
| Scott Sober | Head of Operations |
| Ziad Rouag | Head of Regulatory and Clinical Affairs |
| Idan Steinberg | Head of Engineering |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2025 | SCHEDULE 13G | Filing |
| Oct 28, 2025 | ARS | Filing |
| Oct 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 28, 2025 | DEF 14A | Other definitive proxy statements |
| Oct 24, 2025 | D | Notice of Exempt Offering of Securities |
| Oct 23, 2025 | 8-K | Current Report |
| Oct 17, 2025 | PRE 14A | Other preliminary proxy statements |
| Oct 15, 2025 | 8-K/A | [Amend] Current report |
| Oct 15, 2025 | 8-K | Current Report |
| Aug 14, 2025 | 10-Q | Quarterly Report |